Company / Shareholders' Equity
UroGen Pharma Ltd. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$105.5M
FY2025
5-year range
-$105.5M / $8.4M
FY2021-FY2025
Trend
-61.7%
vs FY2024
Sector context
#199 of 213
Health Care
What the data says
UroGen Pharma Ltd. reports negative total equity of -$105M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$105M in FY2025.
Declined from -$89M to -$105M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 213This company -$105.5M Sector average $2.5B
▼
-104.1% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 61.7% year-over-year.
- Ranks #199 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$105.5M | -61.7% |
| FY2024 | -$65.2M | +27.0% |
| FY2023 | -$89.4M | -1162.2% |
| FY2022 | $8.4M | +0.0% |
| FY2021 | $8.4M | -95.3% |
| FY2020 | $180.3M | +100.1% |
| FY2019 | $90.1M | +0.0% |
| FY2018 | $90.1M | +31.5% |
| FY2017 | $68.5M | +320.2% |
| FY2016 | $16.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026